Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Neuro-Oncology
How would you approach management of a symptomatic meningioma invading the clivus?
Related Questions
What are your top takeaways in Neuro Oncology from ASCO 2025?
What cochlear dose constraint (if any) would you use when treating an acoustic neuroma without serviceable hearing on that side?
How do you manage follow up for patient who was diagnosed with pineal gland germinomas with drop metastatic to the spinal cord?
Is there a role for bevacizimab (IV or IA) for steroid refractory radionecrosis for AVM?
How would you approach a patient with recurrent grade 3 oligodendroglioma (MGMT-methylated, IDH mutant, 1p/19q co-deleted) 1 year after gross total resection and adjuvant chemotherapy and radiation?
In a patient with an R1 resection of a chordoma who has declined proton therapy, what alternative radiation modality would you recommend?
In light of Aizer et al. data presented at ASCO 2025, what is your threshold for offering SRS/SRT in patients with multiple brain metastases?
Are you offering Lutathera for multiple recurrent meningiomas?
Would you consider adjuvant radiation therapy for a grade 1 meningioma with an elevated Ki67?
Would patients receiving targeted therapies be eligible for TTFields for brain metastases?
